CVS Health is partnering with drugmaker Sandoz to produce a near identical version of the blockbuster arthritis treatment Humira.

It will be priced more than 80% lower than the current list price of Humira, which is made by drugmaker Abbvie.

CVS is looking to strengthen its foothold in the biosimilars market, which is expected to grow to $100 billion over the next six years.